<table>
<thead>
<tr>
<th>Registration Number</th>
<th>Sponsor</th>
<th>Study Title</th>
<th>Description</th>
<th>Status</th>
<th>PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>-McG 0201-</td>
<td>Allos Therapeutics, Inc.</td>
<td>A Phase I/II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 Administered to Patients Receiving a Course of Cisplatin and Radiation Therapy for Locally Advanced Carcinoma of the Cervix</td>
<td>TERMINATED</td>
<td>Dr. L. Souhami/Sylvia Papazian</td>
<td></td>
</tr>
<tr>
<td>-McG 0205-</td>
<td>GlaxoSmithKline</td>
<td>An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer</td>
<td>TERMINATED</td>
<td>Dr. V. Hirsh</td>
<td></td>
</tr>
<tr>
<td>-McG 0206-</td>
<td>Lorus Therapeutics Inc.</td>
<td>A Phase III, Double-Blind, Multicenter, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of Virulizin® plus Gemcitabine versus Placebo plus Gemcitabine; Optional Second-Line Therapy may Include Continuation of Virulizin® or Placebo, Alone or in Combination with 5-Fluorouracil</td>
<td>TERMINATED</td>
<td>Dr. M. Thirlwell</td>
<td></td>
</tr>
<tr>
<td>-McG 0207-</td>
<td>Intermune</td>
<td>Actimmune® (Interferon gamma-1b) in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First-line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma</td>
<td>TERMINATED</td>
<td>Dr. W. Miller</td>
<td></td>
</tr>
<tr>
<td>-McG 0209-</td>
<td>American Bioscience.</td>
<td>A Controlled Randomized, Phase III, Multicenter, Open-Label Study of ABI-007 (A Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients with Metastatic Breast Cancer</td>
<td>TERMINATED</td>
<td>Dr. L. Panasci</td>
<td></td>
</tr>
<tr>
<td>-McG 0210-</td>
<td>Peregrine.</td>
<td>A Phase III, Open Label, Randomized Comparative Study of Interstitial 131I-chTNT-1/B (Cotara)Versus Temozolomide for the Treatment of Recurrent Glioblastoma Multiforme (GBM).</td>
<td>TERMINATED</td>
<td>Dr. L. Souhami</td>
<td></td>
</tr>
</tbody>
</table>

Current as of May 16, 2008
-McG 0212- [EFC4690] A09-M71-02B
Phase III Randomized Trial of Concomitant Radiation, Cisplatin and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer
Sanofi Synthelalo/PPD Development
Dr. G. Shenouda
TERMINATED

-McG 0213- [CA163-036-039] A08-M72-02B
A Phase II Study of Novel Epothilone BMS-247550 in Patients with Progressive Small Cell Lung Cancer Which Was Sensitive to First-Line Chemotherapy
Bristol Myers-Squibb
Dr. V. Hirsh
TERMINATED

-McG 0214-
Pegfilgrastim (SD.01) versus Filgrastim (Neupogen) in Cancer Patients. A Randomized Cross-Over Trial to Evaluate Patient Preference and Resource Utilization
Amgen
Dr. W. Miller
TERMINATED

-McG 0215-
A Phase III Multi-Center, Randomized, Open-Label Study to Compare Survival and to Evaluate the Efficacy and Safety of Best Supportive Care Plus Bay 59-8862 Versus Best Supportive Care Only in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC with Brain Metastases).
Bayer
Dr. W. Miller
TERMINATED

-McG 0216- [GN304] A09-M89-02B
Randomized Study of Docetaxel Versus Docetaxel Plus Genasense (G3139 BCL-2 Antisense Oligonucleotide) in Patients with Previously Treated Non-Small Cell Lung Cancer.
Genta
Dr. W. Miller
TERMINATED

-McG 0217- [M34101-039] A09-M82-02A
An International, Multicenter, Randomized, Open-Label Study of PS-341 Versus High-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Millennium Pharmaceuticals/PRA International
Dr. C. Shustik
TERMINATED

-McG 0217ext- [M34101-040] A09-M83-02A
An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients with Multiple Myeloma Who Experienced Relapsed or Progressive Disease After Receiving at Least Four Previous Treatment Regimens or Experienced Progressive Disease After Dexamethasone in Millennium Protocol M34101-039
Millennium Pharmaceuticals/PRA International
Dr. C. Shustik
TERMINATED
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Protocol Code</th>
<th>Treatment Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>-McG 0221-</td>
<td>[304820]</td>
<td>Efficacy and Safety of Subsequent Treatment with 90Y – ibritumomab Tiuxetan Versus no Further Treatment in Patients with Stage III or IV Follicular non-Hodgkin’s Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial. Berlex Canada Inc. Dr. Shustik</td>
</tr>
<tr>
<td>-McG 0222-</td>
<td>[L1069-48]</td>
<td>Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Ligand Dr. W. Miller</td>
</tr>
<tr>
<td>-McG 0223-</td>
<td>[PCYC - 0211]</td>
<td>Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients with Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy. Pharmacyclics Dr. Souhami</td>
</tr>
<tr>
<td>-McG 0225-</td>
<td>[20010145]</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study of Subjects with Previously Untreated Extensive-Stage Small Cell Lung Cancer (SCLC) Treated with Platinum plus Etoposide Chemotherapy with or without Darbepoetin Alfa. Amgen Dr. V. Hirsh</td>
</tr>
<tr>
<td>-McG 0226-</td>
<td>[PGT304]</td>
<td>CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients with Chemotherapy Naïve Advance Non-Small Cell Lung Cancer (NSCLC): A Phase III Study. Cell Therapeutics Dr. V. Hirsh</td>
</tr>
</tbody>
</table>

TERMINATED

Current as of May 16, 2008
A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy, Followed by Thoracic Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer.

*Allos*

Dr. Luis Souhami

**TERMINATED**

**-McG 0228-**

Phase II Trial of CAELYX® and Cyclophosphamide in Metastatic Breast Cancer.

*Schering*

Dr. L. Panasci

**TERMINATED**

**-McG 0230-**

Pilot Phase II Study of Safety and Immunogenicity of an ALVAC –CEA/B7.1 Vaccine Administered with Chemotherapy, Alone or in Combination with Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma.

*Aventis*

Dr. Richard Dalfen

**TERMINATED**

**-McG 0231-**

A Phase II Study of Concurrent and Adjuvant Administration of a Selective Inhibitor of COX-2, Celecoxib, in the Treatment of Stages I/II Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) with Radiation.

*Vanderbilt*

Dr. Sergio Faria

**TERMINATED**